Tiziana Life Sciences Ltd (TLSA) Stock Price, Quote & News

Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7495 2379

Website: www.tizianalifesciences.com

Address:

14/15 Conduit Street, London, United Kingdom

Zenlama Sep. 10 at 3:23 PM

$TLSA

0 · Reply

rp6577 Sep. 10 at 12:52 PM

$TLSA follow the money

0 · Reply

GoCubsGo1124 Sep. 10 at 10:08 AM

$TLSA got to taste 2.08$ premarket there for a minute. 🐂

0 · Reply

Chellybaby Sep. 10 at 10:00 AM

$TLSA nothing modest about purchasing almost 200k shares on the open market. It’s a huge vote of confidence

1 · Reply

GoCubsGo1124 Sep. 10 at 12:02 AM

$TLSA he’ll Yeah, I’d take 7$ all day

0 · Reply

GoCubsGo1124 Sep. 9 at 11:01 PM

$TLSA better than the sells and strong sells of last few weeks. Full send

0 · Reply

HopehelpsU Sep. 9 at 8:54 PM

$TLSA REMINDER: Decision is imminent, I believe the delay is due to the FDA request for additional data... https://www.tizianalifesciences.com/tiziana-life-sciences-files-for-orphan-drug-designation-for-intranasal-foralumab/#:~:text=(Nasdaq%3A%20TLSA)%20(%E2%80%9C,of%20non%2Dactive%20secondary%20progressive

0 · Reply

HopehelpsU Sep. 9 at 8:41 PM

$TLSA First the chairman of Tiziana, now the CEO. They purchased modest amounts, but it's signaling imo, that they believe the shares are going much higher.

0 · Reply

GoCubsGo1124 Sep. 9 at 7:35 PM

$TLSA and we are officially bullish

0 · Reply

GoCubsGo1124 Sep. 9 at 7:35 PM

$TLSA maybe they should start a 100+ million dollar crypto treasury to get it to go to some insane price like some of these other companies. Wild

0 · Reply

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Sep 5, 2025, 8:30 AM EDT - 5 days ago

Tiziana Life Sciences Announces Purchase of Shares by Chairman

Aug 14, 2025, 8:30 AM EDT - 27 days ago

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

Aug 11, 2025, 9:00 AM EDT - 4 weeks ago

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Jul 21, 2025, 7:00 AM EDT - 7 weeks ago

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

Jun 13, 2025, 11:08 PM EDT - 3 months ago

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

Jun 13, 2025, 10:30 AM EDT - 3 months ago

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

Jun 13, 2025, 8:30 AM EDT - 3 months ago

Tiziana Life Sciences to Present at the Bio International Convention

May 23, 2025, 7:00 AM EDT - 3 months ago

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 15, 2025, 8:00 AM EDT - 4 months ago

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 9, 2025, 7:00 AM EDT - 4 months ago

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 6, 2025, 7:00 AM EDT - 4 months ago

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Apr 23, 2025, 7:00 AM EDT - 5 months ago

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

Apr 2, 2025, 8:00 AM EDT - 5 months ago

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Mar 25, 2025, 8:00 AM EDT - 6 months ago

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Mar 17, 2025, 8:00 AM EDT - 6 months ago

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Mar 14, 2025, 8:30 AM EDT - 6 months ago

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Mar 4, 2025, 8:00 AM EST - 6 months ago

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Feb 27, 2025, 8:00 AM EST - 6 months ago

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Feb 25, 2025, 8:00 AM EST - 7 months ago

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Feb 21, 2025, 8:00 AM EST - 7 months ago

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Feb 18, 2025, 8:00 AM EST - 7 months ago

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

Feb 11, 2025, 9:15 AM EST - 7 months ago

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease

Jan 23, 2025, 3:00 PM EST - 8 months ago

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

Jan 23, 2025, 8:54 AM EST - 8 months ago

Tiziana Life Sciences not to engage in capital raising activities for the immediate future

Jan 22, 2025, 4:05 PM EST - 8 months ago

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

Jan 8, 2025, 7:00 AM EST - 8 months ago

Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease

Nov 1, 2024, 1:00 PM EDT - 11 months ago

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

Oct 30, 2024, 10:29 PM EDT - 11 months ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Appoints New Chief Executive Officer

Jul 24, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Granted FDA Fast Track Designation

Jun 28, 2024, 11:01 AM EDT - 1 year ago

Tiziana Receives $3.4 Million in Non-Dilutive Funding

Jun 26, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with Foralumab

May 30, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research

May 13, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab

Apr 25, 2024, 10:00 AM EDT - 1 year ago

Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program

Apr 22, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program

Apr 19, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

Apr 18, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Mar 5, 2024, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease

Jan 8, 2024, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

Jan 5, 2024, 9:30 AM EST - 1 year ago

Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024

Jan 5, 2024, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

Dec 19, 2023, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis

Dec 4, 2023, 7:09 AM EST - 1 year ago

Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar

Nov 30, 2023, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis

Nov 1, 2023, 7:00 AM EDT - 2 years ago

Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023

Oct 18, 2023, 7:00 AM EDT - 2 years ago

Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment

Zenlama Sep. 10 at 3:23 PM

$TLSA

0 · Reply

rp6577 Sep. 10 at 12:52 PM

$TLSA follow the money

0 · Reply

GoCubsGo1124 Sep. 10 at 10:08 AM

$TLSA got to taste 2.08$ premarket there for a minute. 🐂

0 · Reply

Chellybaby Sep. 10 at 10:00 AM

$TLSA nothing modest about purchasing almost 200k shares on the open market. It’s a huge vote of confidence

1 · Reply

GoCubsGo1124 Sep. 10 at 12:02 AM

$TLSA he’ll Yeah, I’d take 7$ all day

0 · Reply

GoCubsGo1124 Sep. 9 at 11:01 PM

$TLSA better than the sells and strong sells of last few weeks. Full send

0 · Reply

HopehelpsU Sep. 9 at 8:54 PM

0 · Reply

HopehelpsU Sep. 9 at 8:41 PM

$TLSA First the chairman of Tiziana, now the CEO. They purchased modest amounts, but it's signaling imo, that they believe the shares are going much higher.

0 · Reply

GoCubsGo1124 Sep. 9 at 7:35 PM

$TLSA and we are officially bullish

0 · Reply

GoCubsGo1124 Sep. 9 at 7:35 PM

$TLSA maybe they should start a 100+ million dollar crypto treasury to get it to go to some insane price like some of these other companies. Wild

0 · Reply

HopehelpsU Sep. 9 at 7:08 PM

$TLSA Orphan Drug Designation PR after the 🔔 would be sweet!

1 · Reply

Jddxn Sep. 9 at 7:00 PM

$TLSA Let it go.

0 · Reply

rp6577 Sep. 9 at 6:27 PM

$TLSA picking up again

0 · Reply

HopehelpsU Sep. 9 at 6:04 PM

$TLSA Nice gain on volume 👌 👍 😀 Let's take $2!

1 · Reply

GoCubsGo1124 Sep. 9 at 4:53 PM

$TLSA 50 crossed over the 5 and 10 and is so close to crossing over the 20 sma. Just send it .

0 · Reply

HopehelpsU Sep. 9 at 3:59 PM

$TLSA Gotta live that higher low put in... ODD and this sucker hits at least $3.... IDGAF, let it climb to $2 before the news. I'm expecting at least a double.....but it won't hold.. Trust me....

0 · Reply

BioRich Sep. 9 at 3:16 PM

$TLSA Looking great here. Definitely a hidden gem, and often confused with $TSLA. I think $TLSA (Tiziana Life Sciences) is the better buy here (Obviously not the same sector, just a general perspective). Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers!

0 · Reply

G101SPM Sep. 9 at 3:01 PM

G101SPM 8/11/2025, 9:12:02 AM $TLSA $2.36 bid. DAC (dollar average cost) $0.846 / last $0.77 (8.15.24). CHANGE EXIT $7.00 (midterm) from $4.00.

0 · Reply

rp6577 Sep. 9 at 2:31 PM

$TLSA looks like it will certainly retest $2 in the short term and then again that 2.4/2.5 level beyond that

0 · Reply

Chellybaby Sep. 9 at 1:44 PM

$TLSA very odd that this news has not had an immediate impact on the SP

1 · Reply

GoCubsGo1124 Sep. 9 at 1:27 PM

@makedatbread88 I know you watch a lot of biotech and insider buys. $TLSA has phase 2 fast track with insider ceo buying 25000 last week and I think 130,000 shares this week. Just something to watch. Keep winning brother

0 · Reply

GoCubsGo1124 Sep. 9 at 1:26 PM

$TLSA sentiment switching to bullish soon? CEO bought more. Was 15000 shares and now over 130,000? Let’s go.

1 · Reply

Market Cap	189.29M
Revenue (ttm)	0.00
Net Income (ttm)	-11.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	196,576
Avg Vol	361,724
Day's Range	N/A - N/A
Shares Out	116.85M
Stochastic %K	69%
Beta	-0.36
Analysts	Strong Buy
Price Target	$3.00